Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shionogi's Anti-Obesity Drug S-2367 Phase IIb Shows Promising Results

This article was originally published in PharmAsia News

Executive Summary

Shionogi announced May 13 that a Phase IIb analysis of anti-obesity drug S-2367 showed good results in both reduced calorie and low calorie tests. Following the analysis, Shionogi decided to continue the trials and plans to start Phase III trials during the second half of next year. Shionogi considers S-2367, which is being developed in the U.S., as one of its major products to expand overseas. Shionogi plans to obtain approval for the drug in 2011 and market it in 2013. The company is also looking for other companies to jointly develop and market the product. (Click here for more - Japanese language

You may also be interested in...

Shionogi Reports Successful Phase II Results For Obesity Treatment Velneperit; Analysts Lukewarm

TOKYO - Osaka-based antibiotics manufacturer Shionogi reported positive results and "significant reduction in body weight" for its Phase II velneperit trial for obesity, but analysts were lukewarm about the results

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts